These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22328117)

  • 1. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.
    Curtis JR; Yun H; Matthews R; Saag KG; Delzell E
    Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1054-60. PubMed ID: 22328117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous zoledronic acid for the treatment of osteoporosis.
    Lewiecki EM
    Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women.
    Gonnelli S; Caffarelli C; Tanzilli L; Pondrelli C; Lucani B; Franci BM; Nuti R
    Bone; 2014 Apr; 61():27-32. PubMed ID: 24389416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence with intravenous zoledronate in elderly patients with osteoporosis.
    Lee YK; Nho JH; Ha YC; Koo KH
    Osteoporos Int; 2012 Sep; 23(9):2329-33. PubMed ID: 22179417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2002 Jul; 3(7):1007-9. PubMed ID: 12083999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
    Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
    Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.
    Hamdy RC
    Drug Des Devel Ther; 2010 Nov; 4():321-35. PubMed ID: 21151620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
    Huang J; Meixner L; Fernandez S; McCutchan JA
    AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intermittent long-term administration of intravenous bisphosphonates for treatment of osteoporosis].
    Miyakoshi N
    Clin Calcium; 2014 Jan; 24(1):93-9. PubMed ID: 24369285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.
    Sambrook P
    Clin Interv Aging; 2007; 2(1):65-72. PubMed ID: 18044076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].
    Hagino H; Hashimoto J; Okano T; Katagiri H
    Clin Calcium; 2008 Aug; 18(8):1176-82. PubMed ID: 18677057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
    Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA
    Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
    Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
    Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.